Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Bayer Discontinues rFVIIa Therapy Trial
 

In May, Bayer AG discontinued a Phase 2/3 trial for BAY 86-6150, its investigational recombinant factor VIIa (rFVIIa) product for the treatment of patients with hemophilia A or hemophilia B and inhibitors. The trial, designed to evaluate the safety and efficacy of BAY 86-6150 in people with inhibitors, was stopped because of the presence of neutralizing inhibitors in subjects. The study, “TReatment with Unique Recombinant rFVIIa STudy (TRUST)” was an open-label, multicenter clinical trial.

 

"Patient safety is our primary concern when designing clinical trials and evaluating BAY 86-6150,” said Kemal Malik, MD, member of the Bayer HealthCare Executive Committee and Head of Global Development. “Due to safety concerns, we are discontinuing the BAY 86-6150 trial as a precautionary measure.”

Source: foxbusiness.com, May 3, 2013; Bayer press release dated May 3, 2013